NDAORALTABLET
Approved
Oct 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPALAN (reserpine) is an oral antihypertensive tablet approved in 1955 that works by depleting catecholamine stores in nerve terminals. It is indicated for hypertension and has been a foundational agent in cardiovascular medicine for nearly 70 years. The drug represents a legacy small-molecule therapy with declining clinical use as newer alternatives dominate modern practice.
LOE Approaching
Limited market opportunity with minimal team investment; roles are likely maintenance-focused rather than growth-oriented.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERPALAN offers minimal career advancement potential given zero linked job opportunities and LOE lifecycle status. Roles would focus on cost management and generic transition rather than innovation, growth, or strategic brand building.
Brand Manager (legacy product stewardship)Generic Affairs Manager
Worked on SERPALAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.